XML 50 R14.htm IDEA: XBRL DOCUMENT
v3.19.2

Fair Value Measurements | 6 Months Ended
--- | ---
Jun. 30, 2019
Fair Value Disclosures [Abstract] |
Fair Value Measurements | Fair Value Measurements The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:
As of June 30, 2019 (In millions) | Total |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Cash equivalents | $ | 1,120.4 |  |  | $ | — |  |  | $ | 1,120.4 |  |  | $ | — |
Marketable debt securities: |  |  |  |  |  |  |
Corporate debt securities | 1,687.7 |  |  | — |  |  | 1,687.7 |  |  | — |
Government securities | 604.4 |  |  | — |  |  | 604.4 |  |  | — |
Mortgage and other asset backed securities | 246.0 |  |  | — |  |  | 246.0 |  |  | — |
Marketable equity securities | 510.0 |  |  | 176.6 |  |  | 333.4 |  |  | — |
Derivative contracts | 88.2 |  |  | — |  |  | 88.2 |  |  | — |
Plan assets for deferred compensation | 29.5 |  |  | — |  |  | 29.5 |  |  | — |
Total | $ | 4,286.2 |  |  | $ | 176.6 |  |  | $ | 4,109.6 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Derivative contracts | $ | 17.5 |  |  | $ | — |  |  | $ | 17.5 |  |  | $ | — |
Contingent consideration obligations | 401.3 |  |  | — |  |  | — |  |  | 401.3 |
Total | $ | 418.8 |  |  | $ | — |  |  | $ | 17.5 |  |  | $ | 401.3 |
As of December 31, 2018 (In millions) | Total |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Cash equivalents | $ | 705.5 |  |  | $ | — |  |  | $ | 705.5 |  |  | $ | — |
Marketable debt securities: |  |  |  |  |  |  |
Corporate debt securities | 2,459.2 |  |  | — |  |  | 2,459.2 |  |  | — |
Government securities | 969.6 |  |  | — |  |  | 969.6 |  |  | — |
Mortgage and other asset backed securities | 260.5 |  |  | — |  |  | 260.5 |  |  | — |
Marketable equity securities | 615.4 |  |  | 51.7 |  |  | 563.7 |  |  | — |
Derivative contracts | 66.9 |  |  | — |  |  | 66.9 |  |  | — |
Plan assets for deferred compensation | 25.4 |  |  | — |  |  | 25.4 |  |  | — |
Total | $ | 5,102.5 |  |  | $ | 51.7 |  |  | $ | 5,050.8 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Derivative contracts | $ | 24.6 |  |  | $ | — |  |  | $ | 24.6 |  |  | $ | — |
Contingent consideration obligations | 409.8 |  |  | — |  |  | — |  |  | 409.8 |
Total | $ | 434.4 |  |  | $ | — |  |  | $ | 24.6 |  |  | $ | 409.8 |
There have been no impairments of our assets measured and carried at fair value during the three and six months ended June 30, 2019. In addition, there were no changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the three and six months ended June 30, 2019. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2018 Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, Summary of Significant Accounting Policies - Fair Value Measurements, to our consolidated financial statements included in our 2018 Form 10-K. Debt Instruments The fair and carrying values of our debt instruments, which are Level 2 liabilities, are summarized as follows:
| As of June 30, 2019 |  | As of December 31, 2018
(In millions) | Fair Value |  | Carrying Value |  | Fair Value |  | Carrying Value
2.900% Senior Notes due September 15, 2020 | $ | 1,507.5 |  |  | $ | 1,491.1 |  |  | $ | 1,489.5 |  |  | $ | 1,480.8 |
3.625% Senior Notes due September 15, 2022 | 1,032.3 |  |  | 996.0 |  |  | 1,000.4 |  |  | 995.5 |
4.050% Senior Notes due September 15, 2025 | 1,867.4 |  |  | 1,738.7 |  |  | 1,745.1 |  |  | 1,737.8 |
5.200% Senior Notes due September 15, 2045 | 1,953.2 |  |  | 1,722.7 |  |  | 1,802.6 |  |  | 1,722.4 |
Total | $ | 6,360.4 |  |  | $ | 5,948.5 |  |  | $ | 6,037.6 |  |  | $ | 5,936.5 |
The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, Indebtedness, to our consolidated financial statements included in our 2018 Form 10-K. Contingent Consideration Obligations In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Fair value, beginning of period | $ | 421.3 |  |  | $ | 498.0 |  |  | $ | 409.8 |  |  | $ | 523.6 |
Changes in fair value | (20.0 | ) |  | 1.9 |  |  | (8.5 | ) |  | (3.7 | )
Payments | — |  |  | — |  |  | — |  |  | (20.0 | )
Fair value, end of period | $ | 401.3 |  |  | $ | 499.9 |  |  | $ | 401.3 |  |  | $ | 499.9 |
As of June 30, 2019 and December 31, 2018, $255.1 million and $265.0 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. For the three and six months ended June 30, 2019, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and expected timing of achieving certain development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time. For the three and six months ended June 30, 2018, changes in the fair value of our contingent consideration obligations were primarily due to an increase in interest rates used to revalue our contingent consideration liabilities, the passage of time and a milestone payment.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration